Anti-Remodelling Effect of Canrenone in Patients with Mild Chronic Heart Failure (AREA IN-CHF study): Final Results

Canrenone on top of optimal treatment for HF did not have additional effects on LVEDV, but it increased EF, and reduced left atrial size and circulating BNP, with potential beneficial effects on outcome. A large-scale randomized study should be implemented to confirm benefits on cardiovascular outcomes in patients with HF in NYHA class II.